XTNT Overview

Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, and Interbody products.

Wall Street analysts forecast XTNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XTNT is1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Xtant Medical Holdings Inc revenue for the last quarter amounts to 33.26M USD, increased 19.04

Xtant Medical Holdings Inc. EPS for the last quarter amounts to 0.01 USD, decreased -125.00

Xtant Medical Holdings Inc (XTNT) has 217 emplpoyees as of March 11 2026.

Today XTNT has the market capitalization of 86.52M USD.